DK1881850T3 - GLP-1-PEGylerede forbindelser - Google Patents
GLP-1-PEGylerede forbindelserInfo
- Publication number
- DK1881850T3 DK1881850T3 DK06759598.3T DK06759598T DK1881850T3 DK 1881850 T3 DK1881850 T3 DK 1881850T3 DK 06759598 T DK06759598 T DK 06759598T DK 1881850 T3 DK1881850 T3 DK 1881850T3
- Authority
- DK
- Denmark
- Prior art keywords
- glp
- compounds
- decreasing
- intestinal
- gastric
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000003247 decreasing effect Effects 0.000 abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000030135 gastric motility Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 230000008991 intestinal motility Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68068805P | 2005-05-13 | 2005-05-13 | |
| PCT/US2006/018284 WO2006124529A1 (en) | 2005-05-13 | 2006-05-11 | Glp-1 pegylated compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1881850T3 true DK1881850T3 (da) | 2011-01-03 |
Family
ID=36926842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06759598.3T DK1881850T3 (da) | 2005-05-13 | 2006-05-11 | GLP-1-PEGylerede forbindelser |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8183340B2 (https=) |
| EP (1) | EP1881850B1 (https=) |
| JP (2) | JP5225074B2 (https=) |
| KR (1) | KR101011081B1 (https=) |
| CN (1) | CN101166545B (https=) |
| AT (1) | ATE482724T1 (https=) |
| AU (1) | AU2006247734B2 (https=) |
| BR (1) | BRPI0609676A2 (https=) |
| CA (1) | CA2608311C (https=) |
| CY (1) | CY1110853T1 (https=) |
| DE (1) | DE602006017202D1 (https=) |
| DK (1) | DK1881850T3 (https=) |
| EA (1) | EA012442B1 (https=) |
| ES (1) | ES2350852T3 (https=) |
| HR (1) | HRP20100543T1 (https=) |
| IL (1) | IL186772A0 (https=) |
| ME (1) | ME02786B (https=) |
| MX (1) | MX2007014052A (https=) |
| NO (1) | NO20076415L (https=) |
| PL (1) | PL1881850T3 (https=) |
| PT (1) | PT1881850E (https=) |
| RS (1) | RS51637B (https=) |
| SI (1) | SI1881850T1 (https=) |
| UA (1) | UA90896C2 (https=) |
| WO (1) | WO2006124529A1 (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2586236T3 (es) | 2005-11-04 | 2016-10-13 | Glaxosmithkline Llc | Procedimientos para administrar agentes hipoglucémicos |
| EP2570133B1 (en) | 2005-11-07 | 2016-03-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| JP5096363B2 (ja) | 2005-12-16 | 2012-12-12 | ネクター セラピューティックス | Ｇｌｐ−１のポリマ複合体 |
| US8501693B2 (en) | 2006-08-04 | 2013-08-06 | Amylin Pharmaceuticals, Llc | Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| RU2477286C2 (ru) | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| AU2008216265B2 (en) | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| GB2448895A (en) * | 2007-05-01 | 2008-11-05 | Activotec Spp Ltd | GLP-1 like compounds and uses thereof |
| EP2164519A2 (en) * | 2007-06-08 | 2010-03-24 | Ascendis Pharma AS | Long-acting polymeric prodrugs of exendin |
| CA2693504A1 (en) * | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009058662A2 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
| US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| US20090149673A1 (en) * | 2007-12-05 | 2009-06-11 | Semprus Biosciences Corp. | Synthetic non-fouling amino acids |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| DK2300035T3 (en) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
| EP2300037B1 (en) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2009155257A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| IT1392655B1 (it) * | 2008-11-20 | 2012-03-16 | Bio Ker S R L | Site-specific monoconjugated insulinotropic glp-1 peptides. |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CN102325539A (zh) | 2008-12-19 | 2012-01-18 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| EP2512518A1 (en) | 2009-12-16 | 2012-10-24 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| CA3070513C (en) | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| WO2011143788A1 (en) * | 2010-05-17 | 2011-11-24 | Zhejiang Beta Pharma Inc. | Novel glucagon like peptide analogs, composition, and method of use |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CN102786590A (zh) * | 2011-05-19 | 2012-11-21 | 江苏豪森药业股份有限公司 | 分枝型peg修饰的glp-1类似物及其可药用盐 |
| BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| RS56173B1 (sr) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| RU2014117678A (ru) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
| JP6374862B2 (ja) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体 |
| CA2877358A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| CN102827270A (zh) * | 2012-09-13 | 2012-12-19 | 无锡和邦生物科技有限公司 | 一种聚乙二醇化艾塞那肽衍生物及其用途 |
| WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
| KR20160021183A (ko) | 2013-06-20 | 2016-02-24 | 노보 노르디스크 에이/에스 | Glp-1 유도체 및 그것의 용도 |
| WO2015000942A1 (en) | 2013-07-04 | 2015-01-08 | Novo Nordisk A/S | Derivatives of glp-1 like peptides, and uses thereof |
| CN112043835B (zh) | 2013-12-06 | 2022-10-21 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
| JP6730278B2 (ja) | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| US10046058B2 (en) | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
| WO2016097108A1 (en) | 2014-12-17 | 2016-06-23 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| WO2016196017A1 (en) | 2015-06-04 | 2016-12-08 | Antriabio, Inc. | Amine pegylation methods for the preparation of site-specific protein conjugates |
| CN106699870A (zh) * | 2016-12-14 | 2017-05-24 | 江苏师范大学 | 长效非洲爪蟾胰高血糖素样肽‑1（glp‑1）类似物及其应用 |
| CN107056921B (zh) * | 2017-03-23 | 2020-06-19 | 桂林八加一药业股份有限公司 | 一种选择性tnfr1拮抗肽sn10及其在炎症性肠病中的应用 |
| EP3717508A1 (en) | 2017-12-01 | 2020-10-07 | The University of Copenhagen | Peptide hormone with one or more o-glycans |
| KR102919209B1 (ko) | 2018-08-10 | 2026-01-28 | 다이아핀 테라퓨틱스, 엘엘씨 | 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료 |
| CN110964116A (zh) * | 2018-09-26 | 2020-04-07 | 北京辅仁瑞辉生物医药研究院有限公司 | GLP1-Fc融合蛋白及其缀合物 |
| CN114478744A (zh) * | 2020-11-13 | 2022-05-13 | 成都奥达生物科技有限公司 | 一种长效glp-1拮抗剂 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| IE50892B1 (en) | 1980-02-11 | 1986-08-06 | Novo Industri As | Process for preparing insulin esters |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5445090A (en) | 1991-07-25 | 1995-08-29 | Mim Industries, Inc. | Interchangeable clamp for use in a sewing machine |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| DK1411075T3 (da) | 1998-03-12 | 2008-10-27 | Nektar Therapeutics Al Corp | Fremgangsmåde til fremstilling af polymerkonjugater |
| SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
| MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
| AU781839B2 (en) | 1999-12-22 | 2005-06-16 | Nektar Therapeutics | Sterically hindered derivatives of water soluble polymers |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| ATE424413T1 (de) * | 2000-06-16 | 2009-03-15 | Lilly Co Eli | Analoge des glucagon-ähnlichen peptids-1 |
| US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
| BR0116024A (pt) * | 2000-12-07 | 2005-12-13 | Lilly Co Eli | Proteìna de fusão heteróloga e uso da mesma |
| MXPA04006679A (es) * | 2002-01-08 | 2004-11-10 | Lilly Co Eli | Analogos extendidos de peptido-1 de tipo glucagon. |
| EP1605897B1 (en) * | 2003-03-19 | 2012-07-25 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
| MXPA05013565A (es) * | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| US20070253966A1 (en) * | 2003-06-12 | 2007-11-01 | Eli Lilly And Company | Fusion Proteins |
| CN1586625A (zh) * | 2004-07-21 | 2005-03-02 | 上海第二医科大学附属瑞金医院 | 用于肿瘤显像和治疗的联合物及其制备方法 |
-
2006
- 2006-05-11 PT PT06759598T patent/PT1881850E/pt unknown
- 2006-05-11 JP JP2008511371A patent/JP5225074B2/ja not_active Expired - Fee Related
- 2006-05-11 CA CA2608311A patent/CA2608311C/en not_active Expired - Fee Related
- 2006-05-11 EA EA200702487A patent/EA012442B1/ru not_active IP Right Cessation
- 2006-05-11 WO PCT/US2006/018284 patent/WO2006124529A1/en not_active Ceased
- 2006-05-11 KR KR1020077026259A patent/KR101011081B1/ko not_active Expired - Fee Related
- 2006-05-11 RS RS20100486A patent/RS51637B/sr unknown
- 2006-05-11 DE DE602006017202T patent/DE602006017202D1/de active Active
- 2006-05-11 AT AT06759598T patent/ATE482724T1/de active
- 2006-05-11 AU AU2006247734A patent/AU2006247734B2/en not_active Ceased
- 2006-05-11 BR BRPI0609676-0A patent/BRPI0609676A2/pt not_active IP Right Cessation
- 2006-05-11 US US11/913,365 patent/US8183340B2/en not_active Expired - Fee Related
- 2006-05-11 PL PL06759598T patent/PL1881850T3/pl unknown
- 2006-05-11 HR HR20100543T patent/HRP20100543T1/hr unknown
- 2006-05-11 DK DK06759598.3T patent/DK1881850T3/da active
- 2006-05-11 ES ES06759598T patent/ES2350852T3/es active Active
- 2006-05-11 ME MEP-2010-486A patent/ME02786B/me unknown
- 2006-05-11 MX MX2007014052A patent/MX2007014052A/es active IP Right Grant
- 2006-05-11 SI SI200630849T patent/SI1881850T1/sl unknown
- 2006-05-11 CN CN2006800147033A patent/CN101166545B/zh not_active Expired - Fee Related
- 2006-05-11 EP EP06759598A patent/EP1881850B1/en active Active
- 2006-11-05 UA UAA200712483A patent/UA90896C2/ru unknown
-
2007
- 2007-10-18 IL IL186772A patent/IL186772A0/en unknown
- 2007-12-12 NO NO20076415A patent/NO20076415L/no not_active Application Discontinuation
-
2010
- 2010-10-21 CY CY20101100945T patent/CY1110853T1/el unknown
-
2012
- 2012-12-06 JP JP2012266820A patent/JP2013079256A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006247734A1 (en) | 2006-11-23 |
| JP2008540565A (ja) | 2008-11-20 |
| CY1110853T1 (el) | 2012-05-23 |
| CA2608311C (en) | 2012-11-27 |
| IL186772A0 (en) | 2008-02-09 |
| UA90896C2 (en) | 2010-06-10 |
| JP5225074B2 (ja) | 2013-07-03 |
| US8183340B2 (en) | 2012-05-22 |
| CA2608311A1 (en) | 2006-11-23 |
| ATE482724T1 (de) | 2010-10-15 |
| DE602006017202D1 (de) | 2010-11-11 |
| CN101166545B (zh) | 2011-06-15 |
| RS51637B (sr) | 2011-10-31 |
| JP2013079256A (ja) | 2013-05-02 |
| SI1881850T1 (sl) | 2011-01-31 |
| AU2006247734B2 (en) | 2011-06-23 |
| US20090215981A1 (en) | 2009-08-27 |
| WO2006124529A1 (en) | 2006-11-23 |
| ES2350852T3 (es) | 2011-01-27 |
| EA200702487A1 (ru) | 2008-04-28 |
| HRP20100543T1 (hr) | 2010-11-30 |
| KR101011081B1 (ko) | 2011-01-25 |
| ME02786B (me) | 2011-10-31 |
| NO20076415L (no) | 2007-12-12 |
| EA012442B1 (ru) | 2009-10-30 |
| BRPI0609676A2 (pt) | 2011-10-18 |
| EP1881850B1 (en) | 2010-09-29 |
| PL1881850T3 (pl) | 2011-03-31 |
| PT1881850E (pt) | 2010-11-26 |
| CN101166545A (zh) | 2008-04-23 |
| KR20080025361A (ko) | 2008-03-20 |
| EP1881850A1 (en) | 2008-01-30 |
| MX2007014052A (es) | 2008-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE482724T1 (de) | Pegylierte glp-1-verbindungen | |
| UA92451C2 (en) | Polyethelene glycol link glp-1 compounds | |
| WO2005091944A3 (en) | Glycol linked fgf-21 compounds | |
| CY1109269T1 (el) | Συνθεσεις πρωτεϊνων συντηξεως αναλογων glp-1 | |
| WO2005113606A3 (en) | Fgf-21 fusion proteins | |
| TW200507870A (en) | GLP-1 analog fusion proteins | |
| WO2007007173A3 (en) | Human anti-madcam antibodies | |
| UA85559C2 (en) | Aminobenzophenone compounds | |
| MX2007007174A (es) | Derivados de cicloalquilamina. | |
| EP1809661A4 (en) | HUMAN INTERFERON-BETA-MUTEIN | |
| ATE532510T1 (de) | Aminosäure-phenoxy-ether, ihre herstellung und verwendungen | |
| TW200637535A (en) | Aryl sulfones and uses related thereto | |
| DK1727817T3 (da) | Azabicyclooctan-3-onderivativer og anvendelse heraf | |
| ATE449066T1 (de) | Biguanidderivate | |
| BRPI0506694A (pt) | análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação | |
| WO2005092362A3 (de) | Pharmazeutisches kombinationspräparat enthaltend ein therapeutisches protein | |
| ATE469134T1 (de) | Pharmazeutisch aktive diazepane | |
| WO2004026319A3 (en) | Pharmaceutical compositions increasing camp useful for the treatment of cancers | |
| ATE378415T1 (de) | In cis regulierte konditionelle genvektoren | |
| ATE458482T1 (de) | Verwendung von amino substituierten benzimidazolen | |
| UA6163U (en) | Anthelmintic drug "anhelmint" | |
| Удоратина | Silver, amber and Chopin | |
| ES1051866U (es) | Mampara plegable mejorada. |